Clinical Trials Directory

Trials / Suspended

SuspendedNCT01990326

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat

Status
Suspended
Phase
Phase 2
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Topokine Therapeutics, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on excess submental fat, also known as double chin. The study will also assess the safety and tolerability of XAF5 Gel.

Conditions

Interventions

TypeNameDescription
DRUGXAF5 Gel
DRUGPlacebo Gel

Timeline

Start date
2013-11-01
Primary completion
2014-06-01
First posted
2013-11-21
Last updated
2016-02-29

Source: ClinicalTrials.gov record NCT01990326. Inclusion in this directory is not an endorsement.

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat (NCT01990326) · Clinical Trials Directory